Focus
GB focuses exclusively on the pharmaceutical, healthcare, and biotechnology industries in China. With an understanding of ongoing policy shifts, a global perspective, and a granular knowledge of China’s players and practices, GB maintains a substantial advantage over diversified consulting firms.

Experience
Since our inception in 2002, we have executed a number of projects ranging across such areas as research and development, industry structure analysis, policy impact studies, partner screening, and sales and marketing strategies and tactics. Our accumulated case work provides us a unique perspective on new projects, allowing us in many cases to accelerate timelines, quickly work through common issues, and dig more deeply into relevant detail for our clients. We focus not only on strategic issues, but also the practicalities of implementing strategies in China’s business environment. Experience has shown us that an excellent strategy for China is useless without significant input from those versed in the realities and constrains on execution in China.
Information advantages
GB leverages the proprietary data and analysis generated by GB Information. Unlike in most developed economies, China lacks quality suppliers of business information, particularly in the healthcare industry. Without access to detailed information on companies, policies, products, market data, and people, consulting and advisory work is dangerous at best and destructive at worst. We leverage the data, analysis, and insights created by GBI to make sure that our client work is built on the solid foundation of reliable information.

For further information, contact us at consulting@generalbiologic.com.